STRC Programmable Recombinases
Core claim
Programmable serine recombinases can integrate large DNA payloads site-specifically into the genome without double-strand breaks. No size limit (unlike AAV). No random integration (unlike lentivirus). Could enable permanent, full-length STRC integration without truncation.
Industry signal
Tome Biosciences acquired for $1.12B (January 2026). Market validating programmable recombinase technology for gene therapy. Profluent and others competing in the space.
Why relevant to STRC
Full STRC (5,325 bp) exceeds AAV limit. Recombinases have no payload size constraint. A single integration event in OHC genome could provide permanent STRC expression without episomal DNA loss over time.
OHCs don’t divide, so episomal AAV might be stable enough — but if OHCs ever turn over (slow lifetime degeneration), integration provides a hedge.
Current limitations
- Programmable recombinases require target “landing pad” sequences in genome — need pre-integration or CRISPR-mediated insertion
- Delivery of recombinase protein to OHCs still unsolved
- Technology mostly validated in dividing cells, less data in post-mitotic neurons/hair cells
- Not yet at clinical stage for cochlear application
Status
Technology watch only. Not actively being developed for this program. Monitor Tome Bio and competitors for cochlear-relevant data.
Trigger for escalation
If recombinase delivery to post-mitotic inner ear cells demonstrated in animal models → elevate to active hypothesis.
Connections
- STRC Hearing Loss — alternative integration approach for full-length STRC
[see-also]STRC Mini-STRC Single-Vector Hypothesis — recombinases would obviate the need for truncation[see-also]STRC AAV Vector Design — recombinases bypass the AAV payload constraint entirely[see-also]STRC Anti-AAV Immune Response Model — recombinase delivery vehicle still faces immune constraints[see-also]Prime Editing for STRC — both are precision-editing alternatives to gene replacement[about]Misha